Appendix A. Summary of patient characteristics and treatment courses.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Age** **(year)** | **Histology** | **Extrapulmonary metastases** | **Previous lung treatment before PZP administration** | **PZP dose (mg)** | **Number of lung metastases** **(subpleural / central type)** | **Best response** | **Cavitation** **(time to cavitation)** | **Types of PTX** | **Time to PTX (after PZP intiation) and severity** | **Treatment of PTX** | **Re-administration of PZP** | **Total treatment periods of PZP (months)** |
| 66  | UPS | Soft tissue | VATS | 600 | 1 (0/1) | PR | **+**, **1m** | Central type | 20m (complete),  | Drainage → VATS | No | 20 |
| 73 | UPS | Pericardium | RFA | 800 | 7 (1/6) | PR | +, 2w | Central typeCentral type | 3m (complete)9m (complete) | Drainage → pleurodesis Unknown (treated in different hospital) | Yes | 8 |
| 57 | UPS | Brain | VATS | 800 | 27 (12/15) | PR | +, 2w | Subpleural typeSubpleural typeSubpleural typeSubpleural typeSubpleural type | 3w (moderate)2m (small)3m (moderate)6m (moderate) 7m (complete) | Drainage → pleurodesisObservationDrainage → pleurodesisDrainage → pleurodesisDrainage |  Yes | 6 |
| 15 | exOS | Bone | - | 800 | 48 (30/18) | PR | +, 2w | Subpleural typeSubpleural typeSubpleural typeSubpleural typeSubpleural typeSubpleural type | 2w (moderate)1m (small)3m (moderate) 4m (moderate)5m (moderate)6m (moderate) | Drainage ObservationDrainage Drainage → pleurodesisDrainage Drainage  | Yes | 4 |
| 76 | LMS | Soft tissue | RFA | 800 | 8 (4/4) | PR | +, 1m |  |  | - |  | 3 |
| 61 | UPS | - | - | 800 | 10 (7/3) | PR | - |  |  | - |  | 23 |
| 29 | ASPS | - | - | 800 | 29 (19/10) | PR | - |  |  | - |  | 51 |
| 44 | exCS | Bone | - | 800 | 23 (18/5) | SD | +, 6m | Subpleural type | 9m (moderate) | Drainage  | No | 9 |
| 49 | UPS | - | - | 400 | 12 (5/7) | PD | - |  |  | - |  | 1 |
| 59 | UPS | - | - | 200 | 3 (0/3) | PR | - |  |  | - |  | 7 |
| 73 | LMS | - | - | 400 | 7 (1/6) | PD | - |  |  | - |  | 2 |
| 67 | AS | Bone, peritoneum | - | 400 | 15 (12/3) | SD | - |  |  | - |  | 1 |
| 22 | CC | Bone, lymph node | - | 400 | 15 (11/4) | SD | - | - | - | - |  | 1 |
| 63 | UPS | Kidney | VATS | 400 | 3 (1/2) | SD |  |  |  |  |  | 4 |
| 68 | UPS | Bone | - | 400 | 8 (2/6) | SD |  |  |  |  |  | 4 |
|  | MFS | Soft tissue | - |  |  伊藤くにひこ12 (6/6) |  |  |  |  |  |  |  |
|  | SS | Brain | VATS |  | しばたたかひろ3 (3/0) |  |  |  |  |  |  |  |
| 62 |  |  |  |  | 68237855 (3/2) |  |  |  |  |  |  |  |
| 71 |  |  |  |  | 65455646 (4/2) |  |  |  |  |  |  |  |
|  | exOS |  | - | 400 | おだひろこ | PD |  |  |  |  |  |  |

AS, angiosarcoma; ASPS, alveolar soft part sarcoma; CC, clear cell sarcoma; exCS, extraskeletal chondrosarcoma; exOS, extraskeletal osteosarcoma; LMS, leiomyosarcoma; m, month(s); PD, progressive disease; PR, partial response; PTX, pneumothorax; PZP, pazopanib; RFA, radio-frequent ablation; SD, stable disease; UPS, undifferentiated pleomorphic sarcoma; VATS, video-associated thoracic surgery; w, week(s)